API

A steroid is a type of organic compound that contains...

read more...

Pharma Intermediate

Pharmaceuticals refer to the drugs and medicines...

read more...

Speciality Chemicals

Specialty chemicals are those chemicals which is produced...

read more...

Products Under Devp.

New Products Under Development In response...

read more...

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2011
(Rs. In Lacs except for share data)
PARTICULARS
For the  Quarter Ended For the Quarter Ended For the Year ended
30th June 2011 30th June 2010 31st Mar 2011
(Gross) Sales / Income from operations 15,689 12,528 52,301
Less : Excise Duty & Sales Tax 881 710 2,659
1. (a) (Net) Sales / Income from operations 14,808 11,818 49,642
(b) Other Operating Income - - -
2. Expenditure
(a). (Increase) / Decrease in stock in trade (812) (426) (1,618)
(b). Consumption of raw materials. 9,354 6,280 27,300
(c). Purchase of Traded Goods 1,780 2,230 8,421
(d). Employees cost 505 403 1,646
(e). Depreciation 435 361 1,548
(f). Other expenditure 2,487 1,809 7,858
(g). Total Expenditure 13,749 10,657 45,155
3. Profit from Operations before Other Income    interest and exceptional items 1,059 1,162 4,487
4. Other Income 4 1 8
5. Profit before Interest & Exceptional Items 1,063 1,162 4,495
6. Interest 400 274 1,348
7. Profit after Interest but before Exceptional Items 663 889 3,147
8. Exceptional Items - - -
9. Profit from Ordinary Activities before Tax 663 889 3,147
10. Tax Expenses (Includes) 201 291 900
Provision for Taxation 163 223 650
Provision for Deferred Taxation 38 68 250
11. Net profit from ordinary Activities after Tax 462 598 2,247
12. Extraordinary Item (net of tax expenses ) - - -
13. Net Profit for the period 462 598 2,247
14. Paid-up Equity Share Capital of Rs.10/- each. 1,211 1,211 1,211
15. Reserves & Surplus (excluding revaluation reserves) - - 14,441
16. Basic E P S (in Rs.) 3.81 4.94 18.56
17. Public Shareholding
Number of Shares 5513823 5833575 5569613
Percentage of Total Shareholding 45.54 48.18 46.00
18. Promoters & Promoter Group
Shareholding
a) Pledged/Encumbered
- Number of Shares NIL NIL NIL
-Percentage of shares( as a percentage of the NIL NIL NIL
total shareholding of promoter and promoter group)
-Percentage of shares( as a percentage of NIL NIL NIL
total share capital of the Company)
b) Non-encumbered
- Number of Shares 6594727 6274975 6538937
-Percentage of shares( as a percentage of 100 100 100
total shareholding of promoter and promoter group)
-Percentage of shares( as a percentage of 54.46 51.82 54.00
total sharecapital of the Company)

Notes :


1. The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 29th July, 2011.

2. Company is operating as a Single Segment Company, engaged in pharmaceuticals business hence, the disclosure requirement As per AS-17 'Segment Reporting' is not attracted.

3. The figures of the previous periods have been regrouped and rearranged wherever necessary.

4. Number of Investors complaints (i) pending at the beginning of quarter :NIL (ii) received during the quarter : 5 (Iii) redressed :5 (iv) pending at the end of the quarter : NIL.

For and on behalf of the Board
FOR AARTI DRUGS LIMITED
Place : Mumbai
Harshit M Savla
DATE : 29th July, 2011
(Jt. Managing Director)
 

Resource Download

Annual Report
Click here to download
annual report
Investor Presentation
Click here to download
Presentation

Copyright © 2010 Aarti Drugs Ltd. All Rights Reserved
Website Developed by : Sri Hema Infotech